Literature DB >> 9454743

De novo CD5+ diffuse large B-cell lymphomas express VH genes with somatic mutation.

M Taniguchi1, K Oka, A Hiasa, M Yamaguchi, T Ohno, K Kita, H Shiku.   

Abstract

To clarify the cellular origin of de novo CD5+ diffuse large B-cell lymphoma (CD5+ DLBL), particularly in comparison with other CD5+ B-cell neoplasms such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), we analyzed the nucleotide sequence of the Ig heavy chain variable region (IgVH) genes of de novo CD5+ DLBL cases. All 4 cases examined had extensive somatic mutations in contrast with CLL or MCL. The VH gene sequences of de novo CD5+ DLBL displayed 86.9% to 95.2% homology with the corresponding germlines, whereas those of simultaneously analyzed CLL and MCL displayed 97.6% to 100% homology. The VH family used was VH3 in 1 case, VH4 in 2 cases, and VH5 in 1 case. In 2 of 4 examined cases, the distribution of replacement and silent mutations over the complementarity determining region and framework region in the VH genes was compatible with the pattern resulting from the antigen selection. Clinically, CD5+ DLBL frequently involved a variety of extranodal sites (12/13) and lymph node (11/13). Immunophenotypically, CD5+ DLBL scarcely expressed CD21 and CD23 (3/13 and 2/13, respectively). These findings indicate that de novo CD5+ DLBL cells are derived from a B-1 subset distinct from those of CLL or MCL.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9454743

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  Role of immunohistochemistry in staging diffuse large B-cell lymphoma (DLBCL).

Authors:  Dipti Talaulikar; Jane Esther Dahlstrom; Bruce Shadbolt; Amy Broomfield; Anne McDonald
Journal:  J Histochem Cytochem       Date:  2008-06-23       Impact factor: 2.479

2.  Prevalence of intravascular large B-cell lymphoma with bone marrow involvement at initial presentation.

Authors:  Masafumi Ito; Yonggoo Kim; Jong Weon Choi; Hiroaki Ozawa; Masahiko Fujino
Journal:  Int J Hematol       Date:  2003-02       Impact factor: 2.490

3.  Primary adrenal diffuse large B cell lymphoma: a clinicopathological and molecular study from China.

Authors:  Jing Zhang; Jian Sun; Jun Feng; Yufeng Luo; Qing Ling; Shafei Wu; Xuan Zeng; Zhiyong Liang
Journal:  Virchows Arch       Date:  2018-05-25       Impact factor: 4.064

4.  Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas.

Authors:  I S Lossos; A A Alizadeh; M B Eisen; W C Chan; P O Brown; D Botstein; L M Staudt; R Levy
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-29       Impact factor: 11.205

Review 5.  Lenalidomide combined with R-GDP in a patient with refractory CD5-positive diffuse large B-cell lymphoma: A promising response and review.

Authors:  Yaping Zhang; Xinfeng Wang; Yifei Liu; Chunfeng Sun; Wenyu Shi; Hongming Huang
Journal:  Cancer Biol Ther       Date:  2018-04-13       Impact factor: 4.742

6.  Utility of a Reverse Phase Protein Array to Evaluate Multiple Biomarkers in Diffuse Large B-Cell Lymphoma.

Authors:  Masaki Suzuki; Atsushi Muroi; Masanori Nojima; Ayumi Numata; Hirotaka Takasaki; Rika Sakai; Tomoyuki Yokose; Yohei Miyagi; Naohiko Koshikawa
Journal:  Proteomics Clin Appl       Date:  2019-11-27       Impact factor: 3.494

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.